Bristol Myers Squibb EBITDA 2010-2022 | BMY

Bristol Myers Squibb annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Bristol Myers Squibb EBITDA for the quarter ending March 31, 2022 was $4.271B, a 17.83% decline year-over-year.
  • Bristol Myers Squibb EBITDA for the twelve months ending March 31, 2022 was $17.857B, a 173.29% increase year-over-year.
  • Bristol Myers Squibb 2021 annual EBITDA was $18.784B, a 435.31% increase from 2020.
  • Bristol Myers Squibb 2020 annual EBITDA was $3.509B, a 47.79% decline from 2019.
  • Bristol Myers Squibb 2019 annual EBITDA was $6.721B, a 1.76% increase from 2018.
Bristol Myers Squibb Annual EBITDA
(Millions of US $)
2021 $18,784
2020 $3,509
2019 $6,721
2018 $6,605
2017 $5,920
2016 $6,297
2015 $2,453
2014 $2,848
2013 $3,654
2012 $5,143
2011 $7,609
2010 $6,678
2009 $6,027
Bristol Myers Squibb Quarterly EBITDA
(Millions of US $)
2022-03-31 $4,271
2021-12-31 $4,437
2021-09-30 $4,884
2021-06-30 $4,265
2021-03-31 $5,198
2020-12-31 $-7,761
2020-09-30 $4,912
2020-06-30 $4,185
2020-03-31 $2,173
2019-12-31 $1,107
2019-09-30 $1,520
2019-06-30 $1,945
2019-03-31 $2,149
2018-12-31 $1,677
2018-09-30 $2,332
2018-06-30 $674
2018-03-31 $1,922
2017-12-31 $895
2017-09-30 $1,371
2017-06-30 $1,506
2017-03-31 $2,148
2016-12-31 $1,208
2016-09-30 $1,664
2016-06-30 $1,705
2016-03-31 $1,720
2015-12-31 $-334
2015-09-30 $1,092
2015-06-30 $143
2015-03-31 $1,552
2014-12-31 $43
2014-09-30 $1,120
2014-06-30 $483
2014-03-31 $1,202
2013-12-31 $1,050
2013-09-30 $998
2013-06-30 $719
2013-03-31 $887
2012-12-31 $1,004
2012-09-30 $766
2012-06-30 $1,207
2012-03-31 $2,166
2011-12-31 $1,863
2011-09-30 $1,853
2011-06-30 $1,974
2011-03-31 $1,919
2010-12-31 $1,654
2010-09-30 $1,749
2010-06-30 $1,722
2010-03-31 $1,553
2009-12-31 $1,434
2009-09-30 $1,658
2009-06-30 $1,596
2009-03-31 $1,339
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $165.407B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00